Matthew Fuchter‘s research on Psammaplin A has proven to be very well received by the public all over the world.
Dr Fuchter and his team at Imperial College in London, published a new way of making psammaplin A which has the potential to inspire novel anti-cancer drugs (OBC Issue 3).
You can see below some of the links highlighting this story.
From the Editorial Office, we would like to congratulate Matthew and his group for a very successful paper and a very promising research.
- Science Daily
- Earth Times
- Gizmag
- Scienceray
- BioMarine
- Pharma Suppliers and News
- Medical News Today
- Medicalnewser.com
- Innovation Toronto
- Cusabio
- Elements4Health
- AlphaGalileo
- Arizona Energy
- BitSnipe
- News Medical
- Wild Shores of Singapore
- Expensiva
- Demencia Digital
- Live Longer Live Stronger
- The Courier
- NHS News details
- BioPortfolio
The article is now free to access for 4 weeks. Don’t miss out and read it now.
New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation
Matthias G. J. Baud, Thomas Leiser, Franz-Josef Meyer-Almes and Matthew J. Fuchter
Org. Biomol. Chem., 2011, 9, 659-662
DOI: 10.1039/C0OB00824A, Communication
